ICER president Steven Pearson at JPM23 (Adrien Villez for Endpoints News)

ICER: Ma­jor­i­ty of pay­er cov­er­age poli­cies sup­port 'key el­e­ments of fair ac­cess' in for­mu­la­ries

The cost-ef­fec­tive­ness watch­dog ICER took a look at 19 drugs and com­pared them to pay­er cov­er­age poli­cies — find­ing in its newest re­port that pay­ers, more of­ten than not, align with cer­tain cri­te­ria of fair ac­cess.

The 46-page fi­nal re­port pub­lished Tues­day ex­am­ined drugs such as Roche’s Hem­li­bra, J&J’s Rem­i­cade and Ste­lara, and Ab­b­Vie’s Hu­mi­ra and com­pared them to cov­er­age poli­cies from 18 for­mu­la­ries, in­clud­ing the 15 largest com­mer­cial for­mu­la­ries, the for­mu­la­ry for the Vet­er­ans Health Ad­min­is­tra­tion and the for­mu­la­ries of the two largest state ACA ex­change plans.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.